Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10289932 | 0.90 | KMT2A (0.37) | KMT2AHSD11B1ALDH1A1HPGDMAPK1 | |
| SCHEMBL4748644 | 0.87 | KMT2A (0.39) | KMT2AHSD11B1ALDH1A1HPGDMAPK1 | |
| SCHEMBL4792235 | 0.80 | KMT2A (0.31) | KMT2A | |
| SCHEMBL4794570 | 0.80 | KMT2A (0.40) | KMT2AHSD11B1ALDH1A1HPGDMAPK1 | |
| SCHEMBL2670055 | 0.79 | ALDH1A1 (0.40) | KMT2AHSD11B1ALDH1A1HPGD | |
| SCHEMBL10289649 | 0.77 | KMT2A (0.33) | KMT2AHSD11B1 | |
| SCHEMBL10306165 | 0.77 | KMT2A (0.38) | KMT2AHSD11B1ALDH1A1HPGDMAPK1 | |
| SCHEMBL4748631 | 0.76 | KMT2A (0.41) | KMT2AHSD11B1ALDH1A1HPGDMAPK1 | |
| SCHEMBL2670372 | 0.69 | ALDH1A1 (0.41) | KMT2AHSD11B1ALDH1A1HPGDMAPK1 | |
| SCHEMBL4748628 | 0.69 | SMYD2 (0.40) | KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| WO-2008082009-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885HSD11B1 3535/4885ALDH1A1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.